ReNeuron Group (OTCMKTS:RNUGF) vs. Akebia Therapeutics (NASDAQ:AKBA) Head-To-Head Contrast

ReNeuron Group (OTCMKTS:RNUGF) and Akebia Therapeutics (NASDAQ:AKBA) are both medical companies, but which is the better stock? We will compare the two companies based on the strength of their risk, analyst recommendations, dividends, institutional ownership, earnings, valuation and profitability.

Profitability

This table compares ReNeuron Group and Akebia Therapeutics’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
ReNeuron Group	N/A	N/A	N/A
Akebia Therapeutics	-8.83%	-62.72%	-5.66%

Volatility and Risk

ReNeuron Group has a beta of -0.64, meaning that its stock price is 164% less volatile than the S&P 500. Comparatively, Akebia Therapeutics has a beta of 0.26, meaning that its stock price is 74% less volatile than the S&P 500.

Institutional & Insider Ownership

33.9% of Akebia Therapeutics shares are owned by institutional investors. 4.3% of Akebia Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Valuation & Earnings

This table compares ReNeuron Group and Akebia Therapeutics”s gross revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
ReNeuron Group	N/A	N/A	N/A	N/A	N/A
Akebia Therapeutics	$236.20 million	1.22	-$5.34 million	($0.08)	-13.38

ReNeuron Group has higher earnings, but lower revenue than Akebia Therapeutics.

Analyst Ratings

This is a breakdown of recent ratings for ReNeuron Group and Akebia Therapeutics, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
ReNeuron Group	0	0	0	0	0.00
Akebia Therapeutics	2	0	3	0	2.20

Akebia Therapeutics has a consensus target price of $4.67, suggesting a potential upside of 336.14%. Given Akebia Therapeutics’ stronger consensus rating and higher possible upside, analysts plainly believe Akebia Therapeutics is more favorable than ReNeuron Group.

Summary

Akebia Therapeutics beats ReNeuron Group on 7 of the 10 factors compared between the two stocks.

About ReNeuron Group

ReNeuron Group plc researches, develops, and commercializes cell-based therapies in the United Kingdom. The company engages in the development of CTX stem cell therapy candidate for treating stroke disability; and human retinal progenitor cell therapy that is in Phase 2 clinical trial for treating retinitis pigmentosa, a blindness-causing disease. It also develops CTX-derived exosomes that are in the pre-clinical stage, which are Nano-sized vesicles secreted by stem cells. In addition, the company licenses ReNcell products. It has a collaboration agreement with University College London to conduct research into the generation of immune cells from induced pluripotent stem cells for anti-cancer cell therapies. The company was founded in 1997 and is headquartered in Pencoed, the United Kingdom.

About Akebia Therapeutics

Akebia Therapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics for patients with kidney diseases. The company’s lead product investigational product candidate is Vafseo (vadadustat), an oral hypoxia-inducible factor prolyl hydroxylase, which is in Phase III development for the treatment of anemia due to chronic kidney disease (CKD) in dialysis-dependent and non-dialysis dependent patients. It offers Auryxia, a ferric citrate that is used to control the serum phosphorus levels in adult patients with DD-CKD on dialysis; and the treatment of iron deficiency anemia in adult patients with CKD not on dialysis. The company’s product pipeline includes AKB-9090, a drug targeting critical-care indications; and AKB-10108, a drug targeting conditions related to premature birth. It has collaboration agreements with Mitsubishi Tanabe Pharma Corporation for the development and commercialization of vadadustat in Japan and other Asian countries, as well as research and license agreement with Janssen Pharmaceutica NV for the development and commercialization of hypoxia-inducible factor prolyl hydroxylase targeted compounds worldwide. Akebia Therapeutics, Inc. was incorporated in 2007 and is headquartered in Cambridge, Massachusetts.